Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.38 |
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 3/20 | 0.32 |
| ▸ | PRKCA | P17252 | 3/20 | 0.32 |
| ▸ | PRKCH | P24723 | 3/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.32 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527166 | 0.95 | HTR2A (0.37) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL6025331 | 0.86 | HTR2A (0.38) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL18527316 | 0.81 | HTR2A (0.37) | HTR2AHTR2CALDH1A1SIGMAR1MAPT | |
| SCHEMBL761931 | 0.74 | HTR2A (0.64) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL30703022 | 0.74 | HTR2A (0.64) | HTR2AHTR2CKDM4EALDH1A1LMNA | |
| SCHEMBL18527335 | 0.73 | HTR2A (0.31) | HTR2AHTR2C | |
| SCHEMBL18202191 | 0.70 | SIGMAR1 (0.48) | HTR2AHTR2CKDM4EALDH1A1HPGD | |
| SCHEMBL5231494 | 0.70 | HTR2A (0.39) | HTR2AHTR2CKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL30819803 | 0.70 | HTR2A (0.39) | HTR2AHTR2CKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL29548539 | 0.69 | HTR2A (0.62) | HTR2AHTR2CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017031325-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-1274711-B1 | NEW AZA-INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-6583134-B2 | Tricyclic aza-indolyl derivatives substituted with ethylamine group is useful for treating central nervous system disorder,cardiovascular disorder, gastrointestinal disorders, diabetes insipidus, and particularly useful for obesity | HOFFMAN-LA ROCHE INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1274711-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-15 | — | — | EP | disclosed |
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | HOFFMANN-LA ROCHE INC. | 2001-09-27 | — | — | US | disclosed |
| WO-2001066548-A1 | NEW AZA-INDOLYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-13 | — | — | WO | disclosed |
| EP-1132389-A1 | New aza-indolyl derivatives for the treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025039-A1 | Aza- indolyl derivatives for treating obesity | GPR119, GIPR, INMT | HTR2A 488/4885HTR2C 410/4885KDM4E 161/4885 |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | HTR2A 189/4885HTR2C 215/4885KDM4E 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.